INS and cancer: In fact, none of the studies reported an overall increase in the incidence of cancer in glargine-treated patients in comparison with those receiving human insulin [34, 39, 40, 45, 90–94], although one of the investigations suggested an increased risk with glargine at high doses only [90]; in one study, the incidence of malignancies with glargine was actually lower than that with human insulin [95].